Non-alcoholic fatty liver is a risk factor for liver cancer

Share This Post

Nonalcoholic fatty liver disease (NAFLD) is a very common disease. To better understand the link between NAFLD and hepatocellular carcinoma (HCC) risk, researchers at Baylor College of Medicine conducted a large Retrospective study published in “Gastroenterology”.

In this study, the research team studied groups from the Veterans Health Administration and followed up for about 11 years. The study included 296,707 patients known to have NAFLD and 296,707 patients without NAFLD. Among NAFLD patients, 490 have HCC, and their risk of developing HCC is much higher than those without NAFLD.

Dr. Fasiha Kanwal, professor and chief of medicine, and colleagues found that NAFLD patients with liver cirrhosis have the highest incidence of HCC each year. The risk of HCC increases with age, and the elderly Spanish with liver cirrhosis is HCC High-risk groups.

“This study provides valuable and powerful information on which of the millions of NAFLD patients are at risk for HCC. This information is an important step forward in our understanding of the disease. For researchers, clinical Doctors and patients have important reference value, ” said Dr. Hashem EI-Serag, professor of gastroenterology at Baylor Medicine and senior author of the paper . Moreover, the results of this study also provide guidance for monitoring and risk adjustment for people at increased risk of liver cancer, such as patients with cirrhosis or diabetes.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy